Lantus and Finasteride Interaction: What Prescribers and Patients Should Know

Insulin glargine (brand names Lantus, Basaglar, Toujeo) is a long-acting basal insulin analog used to manage type 1 and type 2 diabetes. Finasteride (brand names Proscar at 5 mg for benign prostatic hyperplasia, Propecia at 1 mg for androgenetic alopecia) is an oral 5-alpha reductase inhibitor. They are not pharmacologic relatives, and there is no established pharmacokinetic drug interaction between them: insulin glargine is degraded by tissue peptidases rather than liver enzymes, while finasteride is metabolized mainly through hepatic CYP3A4. No dose adjustment of either drug is described in prescribing information because of this combination. That is the established part. What is less settled, and worth walking through deliberately, is whether finasteride's effect on the androgen axis could produce a small, indirect, and clinically negligible shift in glucose control in some men, a plausible but not well-quantified effect that is different from a true drug-drug interaction.

Why this combination comes up

Type 2 diabetes and benign prostatic hyperplasia both become more common with age, and androgenetic alopecia is common in men across a wide age range, so a meaningful number of men end up taking a basal insulin and finasteride at the same time. The practical question a patient or pharmacist is usually asking is simple: does starting finasteride mean an insulin dose needs to change? The direct answer is no. The more interesting question, and the one this page is built to answer honestly, is whether there is any biologically plausible reason for glucose readings to move at all, and if so, how a patient would tell the difference between that and coincidence.

Why there is no pharmacokinetic interaction

Insulin glargine is a recombinant human insulin analog. After subcutaneous injection it forms microprecipitates at the neutral pH of subcutaneous tissue and is released slowly into circulation, where it is broken down by tissue and endosomal peptidases into active metabolites. This clearance pathway does not involve the cytochrome P450 system or P-glycoprotein transport, so insulin glargine has no mechanism by which it would compete with, inhibit, or be affected by a drug that is cleared through those routes. The Lantus prescribing information describes this mechanism and states that dedicated drug interaction studies have not been performed because none are expected based on how the drug is metabolized (per the Lantus prescribing information, which describes this mechanism and notes that dedicated drug interaction studies have not been performed because none are expected based on how the drug is metabolized).

Finasteride is an oral small molecule cleared primarily by CYP3A4, with a minor contribution from CYP3A5. At the doses used for hair loss (1 mg) or BPH (5 mg), finasteride is not considered a clinically significant inhibitor or inducer of major CYP enzymes and has no known effect on P-glycoprotein. The Proscar prescribing information does not list insulin or insulin glargine as an interacting drug (FDA label, Proscar; verify current label version before citing exact wording).

Because one drug is cleared by peptidases in subcutaneous and interstitial tissue and the other by a hepatic CYP enzyme, there is no shared enzyme, transporter, or binding site for the two drugs to compete over. That is the mechanistic basis for the "no known interaction" rating most drug interaction checkers assign to this pair, and it is the strongest and most reliable claim on this page.

The pharmacodynamic question: androgens, DHT, and glucose

The more nuanced question is indirect: could finasteride's effect on the androgen axis change insulin sensitivity enough to matter clinically? Finasteride inhibits type II 5-alpha reductase, which blocks the conversion of testosterone to dihydrotestosterone (DHT). This lowers serum DHT and produces a modest compensatory rise in serum testosterone; the magnitude differs by dose (5 mg for BPH versus 1 mg for alopecia) and is described in the respective FDA labeling.

Separately, there is a body of observational and interventional literature suggesting that low testosterone is associated with insulin resistance in some men, and that testosterone replacement therapy in hypogonadal men has been associated with improvements in measures of insulin sensitivity in some trials and meta-analyses. If that relationship is real, one could reason that any testosterone increase, including the modest one produced by finasteride, might nudge insulin sensitivity in a favorable direction.

This chain of reasoning is plausible but not established as a clinically meaningful effect of finasteride specifically. The testosterone increase attributable to finasteride is small relative to the increase produced by exogenous testosterone therapy, and no clinical trial or pharmacovigilance signal has demonstrated a measurable change in insulin requirements attributable to finasteride. Reviews of metabolic outcomes in men taking 5-alpha reductase inhibitors have reported inconsistent effects on fasting glucose and HbA1c across cohorts, and the clinical relevance of finasteride's testosterone effect on glycemic control specifically has not been quantified in a way that would justify a numeric claim here. Readers should treat any statement of an exact glucose or HOMA-IR change attributable to finasteride as unverified until checked against the primary literature.

Separately, a large cardiovascular safety trial of testosterone replacement therapy in men with hypogonadism and elevated cardiovascular risk (the TRAVERSE trial, published in the New England Journal of Medicine in 2023) is often cited in this context, but it evaluated testosterone therapy, not finasteride, and its glycemic subgroup findings should be pulled from the original publication rather than restated here from memory.

What this means in practice

Finasteride does not appear on lists of medications that require insulin dose adjustment in diabetes management guidelines from bodies such as the American Diabetes Association (ADA Standards of Care, Pharmacologic Approaches to Glycemic Treatment; confirm current-year edition before citing). Drugs that genuinely require proactive insulin adjustment work through direct glucoregulatory mechanisms: systemic corticosteroids raise blood glucose and blunt insulin action; sulfonylureas and other insulin secretagogues add to hypoglycemia risk when combined with insulin; atypical antipsychotics and some antiretrovirals can worsen glycemic control. Finasteride has no known effect on pancreatic beta-cell function, hepatic glucose output, peripheral glucose uptake, or counter-regulatory hormone secretion, which is why it is not grouped with those drugs.

Evidence-status interaction assessment

Blood glucose monitoring guidance

Even absent a known interaction, it is reasonable to watch blood glucose for a short period whenever any new medication is started in a patient using insulin, simply because coincidental illness, dietary change, or an unrelated new prescription can move glucose readings around the same time. Practical steps:

• Continue the existing insulin glargine dose without a preemptive change when starting finasteride.
• Check fasting blood glucose daily for one to two weeks after starting finasteride.
• Note any reading below 70 mg/dL or persistently above the individualized target range.
• Bring a pattern of repeated out-of-range readings to the prescribing clinician rather than adjusting the insulin dose independently.
• If using a continuous glucose monitor, review the ambulatory glucose profile after about two weeks for any shift in time-in-range.

There is no established expectation that finasteride alone will shift these numbers. The monitoring above is a general precaution around any new medication in a person using insulin, not a finasteride-specific protocol.

Symptoms that can be confused between the two drugs

Fatigue and, less commonly, dizziness or mood changes have been reported with finasteride use. These symptoms overlap with what a person might feel during a low or high blood glucose episode. Because a fingerstick or CGM check takes seconds and removes the ambiguity, patients on both medications should check glucose before attributing a symptom to either drug.

When to involve the prescriber

Routine dose adjustment is not needed for the insulin glargine and finasteride combination. It is reasonable to contact the prescribing clinician if:

• Fasting glucose shifts substantially from the patient's usual baseline after starting finasteride, since this points toward another cause that needs investigating.
• Testosterone replacement therapy is started or stopped, since that has a larger and better-documented effect on insulin sensitivity than finasteride alone, and glycemic monitoring after starting testosterone therapy in men with diabetes on insulin is a recommendation found in endocrine society guidance on testosterone therapy (verify the exact wording and edition of the current guideline before quoting it directly).
• The patient switches from finasteride to dutasteride, which inhibits both type I and type II 5-alpha reductase and produces more complete DHT suppression. Dutasteride is also cleared by CYP3A4 and has no established insulin interaction, but a broader enzymatic inhibition profile is a reasonable trigger for a fresh medication review.

Evidence boundary

What is established: insulin glargine and finasteride are cleared through entirely separate pathways, neither FDA label lists the other as an interacting drug, and no dose adjustment is described for this combination. What is plausible but unproven: finasteride's modest testosterone increase might, by extension from testosterone-replacement literature, nudge insulin sensitivity slightly, but this has not been demonstrated for finasteride itself in a controlled study. What is not established: any case of finasteride meaningfully altering insulin requirements, any numeric glucose or HbA1c effect attributable to finasteride, or a specific risk profile for the three-drug combination of insulin, finasteride, and testosterone therapy taken together. Readers and clinicians relying on exact effect sizes for testosterone and insulin sensitivity, or on trial-level glycemic subgroup data from testosterone cardiovascular safety trials, should pull those numbers from the original publications rather than from secondary summaries.

This article reflects a review of FDA prescribing information and general diabetes and endocrinology literature available at the time of writing. Exact numeric findings attributed to specific trials or meta-analyses should be verified against the primary publication before being used in a clinical decision or restated as a precise figure. This page has not yet completed qualified medical review.